

**> PRESS RELEASE / 5 MAY 2015**

---

**Coloplast delivers H1 interim report in line with guidance after a good second quarter performance**

Coloplast delivered organic growth of 7% in the first six months of the 2014/15 financial year, increasing revenue measured in Danish kroner by 11% to DKK 6,748 million.

EBIT before special items was up by 11% to DKK 2,213 million, with the EBIT margin before special items at 33%, versus 33% in H1 2013/14.

Coloplast continues to deliver stable growth in all business areas and in all markets. Organic sales growth by business area was as follows: Ostomy Care 6%, Continence Care 8%, Urology Care 5% and Wound & Skin Care 9%. Coloplast grew its European business by 5%, Other Developed Markets by 4% and Emerging Markets by 20%.

**Improvements achieved in the second quarter**

“While the first quarter didn’t quite meet our expectations, we managed to improve our performance in the second quarter, achieving 8% organic growth. That lifts our growth rate for the half-year reporting period to 7%, which is in line with our guidance,” said Coloplast CEO Lars Rasmussen.

“We have a positive underlying business performance, and we’re delivering solid results in several of our markets and business areas. In Europe, France and Italy delivered positive performances, and in our Emerging Markets, China continues to produce good results,” said Mr Rasmussen, and he continued: “I would also like to note that our latest ostomy care product, the SenSura Mio, is adding to our growth and that we’ve now launched our latest catheter, the SpeediCath Compact Eve, in ten different countries.”

**Paying interim dividends and maintaining guidance for the 2014/2015 financial year**

The Board of Directors has resolved that the company will pay an interim dividend of DKK 4.50 per share following the release of the first-half interim report, for a total dividend pay-out of DKK 953 million.

Based on the H1 interim report, Coloplast continues to expect full-year organic revenue growth of 8-9% and of about 13-14% in DKK. Coloplast continues to expect the EBIT margin to be about 34%, both at constant exchange rates and in DKK.

For further information, click [here](#) to read the H1 Interim Report.

[www.coloplast.com](http://www.coloplast.com)

**PRESS CONTACT**

Simon Mehl Augustesen  
Senior Manager, Media Relations  
+45 4911 3488  
[dkxia@coloplast.com](mailto:dkxia@coloplast.com)

## INVESTOR RELATIONS

Ian Christensen

Vice President, Investor Relations

+45 4911 1301

[dkisec@coloplast.com](mailto:dkisec@coloplast.com)

Financial highlights and key ratios DKKm	6M 2014/15	6M 2013/14	Change
Revenue	6,748	6,080	11%
EBIT	2,213	1,997	11%

EBIT margin	33%	33%	-
-------------	-----	-----	---

Sales performance by business area	6M 2014/15 DKKm	6M 2013/14 DKKm	Organic growth	Reported growth
Ostomy Care	2,699	2,491	6%	8%
Continence Care	2,430	2,159	8%	13%
Urology Care	661	594	5%	11%
Wound & Skin Care	958	836	9%	15%
<b>Revenue</b>	<b>6,748</b>	<b>6,080</b>	<b>7%</b>	<b>11%</b>